• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To Baxter International (BAX) Novum LVP Infusion Pump Class Action Allegations

    Simply Wall St·12/23/2025 15:12:27
    Listen to the news
    • In December 2025, law firm Levi & Korsinsky, LLP notified investors of a class action securities lawsuit against Baxter International, alleging the company misled the market about safety issues and performance of its Novum LVP infusion pump between February 2022 and October 2025.
    • The complaint centers on claims that Baxter knew of serious Novum LVP malfunctions and related patient harm but relied on insufficient customer alerts instead of fully addressing the product’s alleged design flaws.
    • We’ll now examine how allegations of systemic Novum LVP defects and related legal risks may reshape Baxter’s existing investment narrative.

    Find companies with promising cash flow potential yet trading below their fair value.

    Baxter International Investment Narrative Recap

    To own Baxter today, you need to believe it can stabilize its core hospital products, rebuild profitability and manage its balance sheet, despite recent operational and legal headwinds. The Novum LVP class action raises the stakes around product quality and disclosure, and could intensify scrutiny on what was already a key short term risk: execution on infusion pump reliability and any associated revenue or margin impact.

    The most directly relevant recent update is Baxter’s late November 2025 credit agreement amendment, which temporarily loosens leverage covenants while the company tenders up to US$600,000,000 of near term notes. Against new legal uncertainty around Novum LVP, these financing steps put an additional spotlight on liquidity, debt service capacity and the company’s ability to absorb potential litigation or remediation costs without further pressuring its capital structure.

    But beneath the legal headlines, investors also need to be aware that...

    Read the full narrative on Baxter International (it's free!)

    Baxter International's narrative projects $12.1 billion revenue and $913.6 million earnings by 2028.

    Uncover how Baxter International's forecasts yield a $23.80 fair value, a 25% upside to its current price.

    Exploring Other Perspectives

    BAX Earnings & Revenue Growth as at Dec 2025
    BAX Earnings & Revenue Growth as at Dec 2025

    Seven members of the Simply Wall St Community currently peg Baxter’s fair value anywhere between about US$14.80 and US$20,500.83, underlining how far opinions can spread. Set against this, allegations around systemic Novum LVP defects and legal risk could be a central factor many will want to reassess when comparing these different views on the company’s future performance.

    Explore 7 other fair value estimates on Baxter International - why the stock might be worth 22% less than the current price!

    Build Your Own Baxter International Narrative

    Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

    Searching For A Fresh Perspective?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.